NASDAQ:OCX

OncoCyte - OCX Stock Forecast, Price & News

$0.73

-0.01 (-1.36%)

(As of 10/7/2022 05:12 PM ET)

Add

Compare

Today's Range: $0.72
▼
$0.75
50-Day Range: $0.71
▼
$0.99
52-Week Range: $0.68
▼
$3.73

Volume: 106,009 shs
Average Volume: 457,638 shs
Market Capitalization: $86.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.94

OncoCyte MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 300.2% Upside
$2.94 Price Target
Short Interest: Healthy
2.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.97
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$65,500 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.42) to ($0.39) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

305th out of 1,075 stocks

Diagnostic Substances Industry

7th out of 15 stocks

3.4

Analyst's Opinion

Consensus Rating
OncoCyte has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.94, OncoCyte has a forecasted upside of 300.2% from its current price of $0.73.
Amount of Analyst Coverage
OncoCyte has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.09% of the outstanding shares of OncoCyte have been sold short.
Short Interest Ratio / Days to Cover
OncoCyte has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in OncoCyte has recently decreased by 8.15%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
OncoCyte does not currently pay a dividend.
Dividend Growth
OncoCyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OCX.

0.6

News and Social Media Coverage

News Sentiment
OncoCyte has a news sentiment score of -0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for OncoCyte this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for OCX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.06% of the stock of OncoCyte is held by insiders.
Percentage Held by Institutions
89.41% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OncoCyte are expected to grow in the coming year, from ($0.42) to ($0.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OncoCyte is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OncoCyte is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OncoCyte has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OncoCyte (NASDAQ:OCX) Stock

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

October 6, 2022 | finance.yahoo.com

DetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer

October 6, 2022 | globenewswire.com

DetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer - GlobeNewswire

October 7, 2022 | Investing Trends (Ad)

Investors See Opportunity in Huge Global Demand for Lithium

The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.

October 3, 2022 | reuters.com

OCX.N - OncoCyte Corp | Stock Price & Latest News | Reuters

September 30, 2022 | americanbankingnews.com

Brokerages Set OncoCyte Co. (NASDAQ:OCX) Price Target at $2.90

September 26, 2022 | finance.yahoo.com

OncoCyte (OCX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

September 23, 2022 | nasdaq.com

Strength Seen in Cano Health, Inc. (CANO): Can Its 32.2% Jump Turn into More Strength? - Nasdaq

September 15, 2022 | reuters.com

OCX.A - OncoCyte Corp | Stock Price & Latest News | Reuters

October 7, 2022 | Investing Trends (Ad)

Investors See Opportunity in Huge Global Demand for Lithium

September 7, 2022 | globenewswire.com

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS - GlobeNewswire

September 7, 2022 | finance.yahoo.com

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS

September 2, 2022 | finance.yahoo.com

Here's Why OncoCyte (OCX) Looks Ripe for Bottom Fishing - Yahoo Finance

September 2, 2022 | nasdaq.com

Here's Why OncoCyte (OCX) Looks Ripe for Bottom Fishing - Nasdaq

September 2, 2022 | globenewswire.com

Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference - GlobeNewswire

August 31, 2022 | benzinga.com

ONEXoration (OCX) – Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference - Benzinga

August 31, 2022 | finance.yahoo.com

Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference

August 30, 2022 | streetinsider.com

OncoCyte (OCX) Awarded Five-Year VA Contract for DetermaRx - StreetInsider.com

August 30, 2022 | benzinga.com

ONEXoration (OCX) – Oncocyte shares are trading higher after the company announced it received a 5 year V - Benzinga

August 30, 2022 | finance.yahoo.com

Oncocyte Announces Five-Year VA Contract for DetermaRx

August 24, 2022 | globenewswire.com

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer - GlobeNewswire

August 24, 2022 | finance.yahoo.com

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

August 20, 2022 | nasdaq.com

Andrew Arno Is The Independent Chairman of OncoCyte Corporation (NASDAQ:OCX) And They Just Picked Up 123% More Shares - Nasdaq

August 20, 2022 | ca.finance.yahoo.com

Insider Buying: The OncoCyte Corporation (NASDAQ:OCX) Independent Chairman Just Bought 123% More Shares

August 19, 2022 | globenewswire.com

Breast Cancer Screening Market Size to Reach US$ 4.48 billion by 2030| Exclusive Report by Growth Plus Reports - GlobeNewswire

August 18, 2022 | nasdaq.com

Thursday 8/18 Insider Buying Report: FOX, OCX

August 18, 2022 | benzinga.com

OncoCyte And 2 Other Stocks Under $1 Insiders Are Aggressively Buying - Benzinga

August 13, 2022 | finance.yahoo.com

Oncocyte Implements Cost Reduction Initiatives, Realigns Operations

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Company Calendar

Last Earnings: 8/10/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OCX
CUSIP: N/A
CIK: 1642380
Web: oncocyte.com
Phone: 949 409 7600
Fax: 510-521-3389
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.94
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +302.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-64,100,000.00
Net Margins: -846.58%
Pretax Margin: -845.37%
Return on Equity: -54.28%
Return on Assets: -25.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.49
Quick Ratio: 3.49

Sales & Book Value

Annual Sales: $7.73 million
Price / Sales: 11.20
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.71 per share
Price / Book: 1.03

Miscellaneous

Outstanding Shares: 118,609,000
Free Float: 113,793,000
Market Cap: $86.58 million
Optionable: Optionable
Beta: 1.70

Key Executives

Mr. Ronald A. Andrews Jr. (Age 62)
CEO & Director
Comp: $801.84k

Mr. Mitchell S. Levine (Age 62)
Corp. Devel. Officer
Comp: $480.71k

Dr. Douglas T. Ross M.D. (Age 62)
Ph.D., Chief Science Officer
Comp: $558.94k

Ms. Gisela A. Paulsen (Age 56)
COO & Pres

Mr. Anish John (Age 52)
Chief Financial Officer

Dr. Ekkehard Schutz M.D.
Ph.D., Chief Technology Officer

Mr. William Annett (Age 68)
Advisor

Ms. Padma Sundar (Age 48)
Chief Commercial Officer

Mr. Robert S. Seitz (Age 58)
Head of Immune Oncology

Dr. Michael D. West Ph.D. (Age 69)
Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OCX Stock - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OCX shares.
View OCX analyst ratings or view top-rated stocks.
What is OncoCyte's stock price forecast for 2022?: 5 equities research analysts have issued 12 month price targets for OncoCyte's stock. Their OCX share price forecasts range from $1.50 to $5.00. On average, they predict the company's share price to reach $2.94 in the next twelve months. This suggests a possible upside of 302.7% from the stock's current price.
View analysts price targets for OCX or view top-rated stocks among Wall Street analysts.
How have OCX shares performed in 2022?: OncoCyte's stock was trading at $1.89 on January 1st, 2022. Since then, OCX shares have decreased by 61.4% and is now trading at $0.73.
View the best growth stocks for 2022 here.
When is OncoCyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our OCX earnings forecast.

How were OncoCyte's earnings last quarter?: OncoCyte Co. (NASDAQ:OCX) released its quarterly earnings data on Wednesday, August, 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $2.50 million. OncoCyte had a negative net margin of 846.58% and a negative trailing twelve-month return on equity of 54.28%.
What other stocks do shareholders of OncoCyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).
What is OncoCyte's stock symbol?: OncoCyte trades on the NASDAQ under the ticker symbol "OCX."
How do I buy shares of OncoCyte?: Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is OncoCyte's stock price today?: One share of OCX stock can currently be purchased for approximately $0.73.
How much money does OncoCyte make?: OncoCyte (NASDAQ:OCX) has a market capitalization of $86.59 million and generates $7.73 million in revenue each year. The company earns $-64,100,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.
How can I contact OncoCyte?: OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at 949 409 7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.

This page (NASDAQ:OCX) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

OncoCyte - OCX Stock Forecast, Price & News

OncoCyte MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month